Nuvasive Inc (NASDAQ:NUVA) Institutional Investors Sentiment

September 8, 2017 - By Maria Brooks

 Nuvasive Inc (NASDAQ:NUVA) Institutional Investors Sentiment

Sentiment for Nuvasive Inc (NASDAQ:NUVA)

Nuvasive Inc (NASDAQ:NUVA) institutional sentiment decreased to 0.93 in Q4 2016. Its down -0.58, from 1.51 in 2016Q3. The ratio dropped, as 122 hedge funds increased or started new holdings, while 131 sold and decreased stakes in Nuvasive Inc. The hedge funds in our partner’s database now possess: 53.03 million shares, up from 50.46 million shares in 2016Q3. Also, the number of hedge funds holding Nuvasive Inc in their top 10 holdings increased from 4 to 6 for an increase of 2. Sold All: 37 Reduced: 94 Increased: 81 New Position: 41.

Nuvasive, Inc. is a medical device company. The company has market cap of $3.04 billion. The Firm focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. It has a 96.51 P/E ratio. The Company’s product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

The stock decreased 2.04% or $1.25 during the last trading session, reaching $60.07. About shares traded. NuVasive, Inc. (NASDAQ:NUVA) has risen 33.31% since September 8, 2016 and is uptrending. It has outperformed by 16.61% the S&P500.

Hood River Capital Management Llc holds 3.76% of its portfolio in NuVasive, Inc. for 640,690 shares. Sectoral Asset Management Inc owns 498,689 shares or 3.72% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 2.82% invested in the company for 70,000 shares. The New York-based Pura Vida Investments Llc has invested 2.59% in the stock. Ghost Tree Capital Llc, a New York-based fund reported 150,000 shares.#img1#

Since January 1, 0001, it had 0 insider buys, and 1 sale for $1.18 million activity.

NuVasive, Inc. (NASDAQ:NUVA) Ratings Coverage

Ratings analysis reveals 80% of Nuvasive Inc.’s analysts are positive. Out of 20 Wall Street analysts rating Nuvasive Inc., 16 give it “Buy”, 1 “Sell” rating, while 3 recommend “Hold”. The lowest target is $56 while the high is $9000. The stock’s average target of $76.94 is 28.08% above today’s ($60.07) share price. NUVA was included in 41 notes of analysts from July 29, 2015. The firm has “Buy” rating given on Wednesday, July 27 by Jefferies. On Thursday, June 29 the stock rating was maintained by Jefferies with “Buy”. The stock of NuVasive, Inc. (NASDAQ:NUVA) has “Buy” rating given on Friday, July 28 by Canaccord Genuity. Canaccord Genuity upgraded it to “Buy” rating and $58 target in Tuesday, October 6 report. The stock has “Overweight” rating by Barclays Capital on Wednesday, July 27. The firm has “Neutral” rating given on Friday, December 11 by Bank of America. Needham downgraded the shares of NUVA in report on Monday, August 28 to “Sell” rating. The firm has “Buy” rating given on Wednesday, August 16 by UBS. The stock of NuVasive, Inc. (NASDAQ:NUVA) has “Buy” rating given on Wednesday, June 28 by Cowen & Co. Cowen & Co maintained NuVasive, Inc. (NASDAQ:NUVA) on Friday, July 28 with “Buy” rating.

More important recent NuVasive, Inc. (NASDAQ:NUVA) news were published by: which released: “NuVasive Appoints Rajesh J. Asarpota As Chief Financial Officer” on August 15, 2017, also published article titled: “NuVasive Receives FDA 510(k) Clearance For Leading EOS Innovation”, published: “NuVasive Announces World-Class Innovation Center At San Diego Headquarters” on August 29, 2017. More interesting news about NuVasive, Inc. (NASDAQ:NUVA) was released by: and their article: “Nuvasive Inc (NUVA) Chairman & CEO Gregory T Lucier Bought $331100 of Shares” with publication date: August 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.